Literature DB >> 26876451

Epigenetic regulation of cardiac fibrosis.

Matthew S Stratton1, Timothy A McKinsey2.   

Abstract

Fibrosis is defined as excess deposition of extracellular matrix (ECM), resulting in tissue scarring and organ dysfunction. In the heart, fibrosis may be reparative, replacing areas of myocyte loss with a structural scar following infarction, or reactive, which is triggered in the absence of cell death and involves interstitial ECM deposition in response to long-lasting stress. Interstitial fibrosis can increase the passive stiffness of the myocardium, resulting in impaired relaxation and diastolic dysfunction. Additionally, fibrosis can lead to disruption of electrical conduction in the heart, causing arrhythmias, and can limit myocyte oxygen availability and thus exacerbate myocardial ischemia. Here, we review recent studies that have illustrated key roles for epigenetic events in the control of pro-fibrotic gene expression, and highlight the potential of small molecules that target epigenetic regulators as a means of treating fibrotic cardiac diseases.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Cardiac; Epigenetics; Fibrosis

Mesh:

Year:  2016        PMID: 26876451      PMCID: PMC4987078          DOI: 10.1016/j.yjmcc.2016.02.011

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  121 in total

Review 1.  Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases.

Authors:  Frank J Dekker; Thea van den Bosch; Nathaniel I Martin
Journal:  Drug Discov Today       Date:  2013-11-21       Impact factor: 7.851

Review 2.  The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: A recent update.

Authors:  Shatadal Ghosh; Sharmistha Banerjee; Parames C Sil
Journal:  Food Chem Toxicol       Date:  2015-06-09       Impact factor: 6.023

3.  Brd4 is on the move during inflammation.

Authors:  Yali Xu; Christopher R Vakoc
Journal:  Trends Cell Biol       Date:  2014-10-03       Impact factor: 20.808

4.  Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification.

Authors:  Minjia Tan; Hao Luo; Sangkyu Lee; Fulai Jin; Jeong Soo Yang; Emilie Montellier; Thierry Buchou; Zhongyi Cheng; Sophie Rousseaux; Nisha Rajagopal; Zhike Lu; Zhen Ye; Qin Zhu; Joanna Wysocka; Yang Ye; Saadi Khochbin; Bing Ren; Yingming Zhao
Journal:  Cell       Date:  2011-09-16       Impact factor: 41.582

5.  AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation.

Authors:  Yuanyuan Li; Hong Wen; Yuanxin Xi; Kaori Tanaka; Haibo Wang; Danni Peng; Yongfeng Ren; Qihuang Jin; Sharon Y R Dent; Wei Li; Haitao Li; Xiaobing Shi
Journal:  Cell       Date:  2014-10-23       Impact factor: 41.582

6.  Inhibition of histone acetyltransferase activity by anacardic acid sensitizes tumor cells to ionizing radiation.

Authors:  Yingli Sun; Xiaofeng Jiang; Shujuan Chen; Brendan D Price
Journal:  FEBS Lett       Date:  2006-07-10       Impact factor: 4.124

Review 7.  Molecular mechanisms of curcumin action: signal transduction.

Authors:  Adeeb Shehzad; Young Sup Lee
Journal:  Biofactors       Date:  2013-01-10       Impact factor: 6.113

8.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.

Authors:  Mark A Dawson; Rab K Prinjha; Antje Dittmann; George Giotopoulos; Marcus Bantscheff; Wai-In Chan; Samuel C Robson; Chun-wa Chung; Carsten Hopf; Mikhail M Savitski; Carola Huthmacher; Emma Gudgin; Dave Lugo; Soren Beinke; Trevor D Chapman; Emma J Roberts; Peter E Soden; Kurt R Auger; Olivier Mirguet; Konstanze Doehner; Ruud Delwel; Alan K Burnett; Phillip Jeffrey; Gerard Drewes; Kevin Lee; Brian J P Huntly; Tony Kouzarides
Journal:  Nature       Date:  2011-10-02       Impact factor: 49.962

9.  Functional importance of cardiac enhancer-associated noncoding RNAs in heart development and disease.

Authors:  Samir Ounzain; Iole Pezzuto; Rudi Micheletti; Frédéric Burdet; Razan Sheta; Mohamed Nemir; Christine Gonzales; Alexandre Sarre; Michael Alexanian; Matthew J Blow; Dalit May; Rory Johnson; Jérôme Dauvillier; Len A Pennacchio; Thierry Pedrazzini
Journal:  J Mol Cell Cardiol       Date:  2014-08-19       Impact factor: 5.000

10.  CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.

Authors:  Ariane Hammitzsch; Cynthia Tallant; Oleg Fedorov; Alison O'Mahony; Paul E Brennan; Duncan A Hay; Fernando O Martinez; M Hussein Al-Mossawi; Jelle de Wit; Matteo Vecellio; Christopher Wells; Paul Wordsworth; Susanne Müller; Stefan Knapp; Paul Bowness
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-10       Impact factor: 11.205

View more
  16 in total

1.  Interleukin-10 Inhibits Bone Marrow Fibroblast Progenitor Cell-Mediated Cardiac Fibrosis in Pressure-Overloaded Myocardium.

Authors:  Suresh K Verma; Venkata N S Garikipati; Prasanna Krishnamurthy; Sarah M Schumacher; Laurel A Grisanti; Maria Cimini; Zhongjian Cheng; Mohsin Khan; Yujia Yue; Cindy Benedict; May M Truongcao; Joseph E Rabinowitz; David A Goukassian; Douglas Tilley; Walter J Koch; Raj Kishore
Journal:  Circulation       Date:  2017-06-30       Impact factor: 29.690

2.  Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism.

Authors:  Mark Y Jeong; Ying H Lin; Sara A Wennersten; Kimberly M Demos-Davies; Maria A Cavasin; Jennifer H Mahaffey; Valmen Monzani; Chandrasekhar Saripalli; Paolo Mascagni; T Brett Reece; Amrut V Ambardekar; Henk L Granzier; Charles A Dinarello; Timothy A McKinsey
Journal:  Sci Transl Med       Date:  2018-02-07       Impact factor: 17.956

3.  The potential of targeting epigenetic regulators for the treatment of fibrotic cardiac diseases.

Authors:  Katherine B Schuetze; Keith A Koch; Timothy A McKinsey
Journal:  Future Med Chem       Date:  2016-08-24       Impact factor: 3.808

4.  Overlapping and Divergent Actions of Structurally Distinct Histone Deacetylase Inhibitors in Cardiac Fibroblasts.

Authors:  Katherine B Schuetze; Matthew S Stratton; Weston W Blakeslee; Michael F Wempe; Florence F Wagner; Edward B Holson; Yin-Ming Kuo; Andrew J Andrews; Tonya M Gilbert; Jacob M Hooker; Timothy A McKinsey
Journal:  J Pharmacol Exp Ther       Date:  2017-02-07       Impact factor: 4.030

Review 5.  Myofibroblasts and Fibrosis: Mitochondrial and Metabolic Control of Cellular Differentiation.

Authors:  Andrew A Gibb; Michael P Lazaropoulos; John W Elrod
Journal:  Circ Res       Date:  2020-07-16       Impact factor: 17.367

Review 6.  Epigenetic signatures in cardiac fibrosis, special emphasis on DNA methylation and histone modification.

Authors:  Hui Tao; Zheng-Yu Song; Xuan-Sheng Ding; Jing-Jing Yang; Kai-Hu Shi; Jun Li
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

7.  Epigenetic Regulation of Myofibroblast Phenotypes in Fibrosis.

Authors:  Thu Elizabeth Duong; James S Hagood
Journal:  Curr Pathobiol Rep       Date:  2018-03-16

Review 8.  Regulation of Nrf2 signaling pathway in heart failure: Role of extracellular vesicles and non-coding RNAs.

Authors:  Changhai Tian; Lie Gao; Irving H Zucker
Journal:  Free Radic Biol Med       Date:  2021-03-17       Impact factor: 7.376

Review 9.  Cardiac fibrosis.

Authors:  Nikolaos G Frangogiannis
Journal:  Cardiovasc Res       Date:  2021-05-25       Impact factor: 10.787

10.  Histone chaperone HIRA regulates neural progenitor cell proliferation and neurogenesis via β-catenin.

Authors:  Yanxin Li; Jianwei Jiao
Journal:  J Cell Biol       Date:  2017-05-17       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.